J Appl Biomed 22:208-213, 2024 | DOI: 10.32725/jab.2024.022

Association between mean platelet volume and adiponectin in patients with metabolic syndrome

Milos Marinkovic¹, Jelena Nesic^{1, 2}, Ivica Petrovic^{3, *}, Ivan P Jovanovic⁴, Marija Sekulic⁵, Svetlana Djukic^{1, 2}, Aleksandar Djukic^{1, 3}

¹ University Clinical Center Kragujevac, Serbia

² University of Kragujevac, Faculty of Medical Sciences, Department of Internal Medicine, Kragujevac, Serbia

³ University of Kragujevac, Faculty of Medical Sciences, Department of Pathophysiology, Kragujevac, Serbia

⁴ University of Kragujevac, Faculty of Medical Sciences, Centre for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia

⁵ University of Kragujevac, Faculty of Medical Sciences, Department of Hygiene and Ecology, Kragujevac, Serbia

Background: Metabolic syndrome is a significant pro-inflammatory and pro-coagulant condition. The clinical association of adiponectin, a mainly antidiabetogenic molecule, and its interaction with platelets and platelet indices remains insufficiently investigated.

Objective: The aim of our study was to investigate the association of adiponectin with platelets and platelet indices in patients with metabolic syndrome.

Methods: The investigation was conducted as a cross-sectional study involving 113 subjects: 63 patients with the diagnosis of metabolic syndrome, and 50 healthy controls - with clear inclusion and exclusion criteria. The group of patients with metabolic syndrome was divided into two subgroups according to the platelet/high-density lipoprotein (HDL) ratio.

Results: The subgroup with a higher platelet/HDL ratio was prediabetic. In the same subgroup of patients, a positive correlation between the adiponectin and mean platelet volume (MPV) was seen, while linear regression (95% CI) confirmed the association.

Conclusion: Considering that MPV is the index that indicates average platelet volume and activity, we believe this association with adiponectin can represent a protective compensatory response in patients with metabolic syndrome and prediabetes. Our results provide a basis for a more precise selection of patients in whom the future therapeutic application of recombinant adiponectin would be most effective.

Keywords: Adiponectin; Mean platelet volume; Metabolic syndrome; Platelets

Grants and funding:

This work was supported by a grant from the Faculty of Medical Sciences, the University of Kragujevac, Serbia (JP 01/23) - specifically in providing chemicals for research.

Conflicts of interest:

The authors have no manuscript-related conflict of interest to declare.

Received: June 4, 2024; Revised: September 18, 2024; Accepted: November 20, 2024; Prepublished online: November 20, 2024; Published: December 18, 2024  Show citation